Cited by 361Antibiotics Pharmacokinetics and EfficacyAntimicrobial Resistance in StaphylococcusAntibiotic Use and Resistance

The DOI matches its Crossref record; 96 of the 97 references it cites were found in a registry or an index.

Clinical Pharmacokinetics of Vancomycin

Matzke, G.R., Zhanel, G.G., Guay, D.R.P.·1986·Clinical Pharmacokinetics

DOI 10.2165/00003088-198611040-00001

Open this paper in CoChat — free account

Abstract

Vancomycin utilisation has increased dramatically in the last 10 years due to the increasing clinical significance of infections with methicillin-resistant staphylococci. Recent studies have focused on characterising the disposition of vancomycin in patients and assessing the relationship between serum concentrations and therapeutic as well as adverse effects. Although vancomycin is not appreciably absorbed from the intact gastrointestinal tract, several recent case reports have documented the attainment of therapeutic and potentially toxic vancomycin serum concentrations following oral administration to patients with pseudomembranous colitis. The disposition of parenterally administered vancomycin has been best characterised by a triexponential model. The half-life of the initial phase (t1/2 pi) is approximately 7 minutes, that of the second phase (t1/2 alpha) is approximately 0.5 to 1 hour, while the terminal elimination half-life (t1/2 beta) ranges from 3 to 9 hours in subjects with normal renal function. The volume of the central compartment (Vc) in adults is approximately 0.15 L/kg while the steady-state volume of distribution (Vdss) ranges from 0.39 to 0.97 L/kg. More than 80% of a vancomycin dose is excreted unchanged in the urine within 24 hours after administration, and the concentration of vancomycin in liver tissue and bile has been reported to be at or below detection limits. Vancomycin renal clearance approximates 0.5 to 0.8 of simultaneously determined creatinine or 125I-iothalamate clearances, suggesting that the primary route of renal excretion is glomerular filtration. Recently, non-renal factors such as hepatic conjugation have been proposed as an important route of vancomycin elimination. However, these data are difficult to reconcile with other studies showing minimal non-renal clearance of vancomycin in subjects with end-stage renal disease. As yet, the disposition of vancomycin in patients with hepatic disease has not been adequately defined. Only limited data are available regarding the concentrations of vancomycin in biological fluids other than plasma. The penetration of vancomycin into cerebrospinal fluid (CSF) in patients with and without meningitis has been quite variable. Although early studies suggested that adequate CSF concentrations may not be achieved in subjects with uninflamed meninges, more recent investigations have reported contradictory results. Therapeutic concentrations of vancomycin, i.e. greater than 2.5 mg/L, have, however, been reported in ascitic, pericardial, pleural and synovial fluids. Tissue concentrations of vancomycin have exceeded simultaneous serum concentrations in heart, kidney, liver and lung sp

Integrity signals

Registry

Crossref · 10.2165/00003088-198611040-00001

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Applied pharmacokinetics : principles of therapeutic drug monitoring
Evans, W. E., Schentag, J. J., & Jusko, W. J. (1992) · Medical Entomology and Zoology · Cited by 1,045
Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981
Farber, B. F., & Moellering, R. C. (1983) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.23.1.138 · Cited by 433
Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: Gentamicin in burn patients
Sawchuk, R. J., & Zaske, D. E. (1976) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01086153 · Cited by 361
Pharmacokinetics of vancomycin in patients with various degrees of renal function
Matzke, G. R., McGory, R. W., Halstenson, C. E., & Keane, W. F. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.25.4.433 · Cited by 361
Self-citation
Vancomycin Therapy in Patients with Impaired Renal Function: A Nomogram for Dosage
Moellering, R. C., KROGSTAD, D. J., & GREENBLATT, D. J. (1981) · Annals of Internal Medicine · doi:10.7326/0003-4819-94-3-343 · Cited by 279
Vancomycin Therapy for Methicillin-Resistant Staphylococcus aureus
Sorrell, T. C., PACKHAM, D. R., SHANKER, S., FOLDES, M., & MUNRO, R. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-3-344 · Cited by 253
ORAL VANCOMYCIN FOR ANTIBIOTIC-ASSOCIATED PSEUDOMEMBRANOUS COLITIS
Tedesco, F. J., Gurwith, M., Markham, R. B., Christie, D. L., & Bartlett, J. (1978) · The Lancet · doi:10.1016/s0140-6736(78)91741-5 · Cited by 238
Vancomycin pharmacokinetics in normal and morbidly obese subjects
Blouin, R. A., Bauer, L. A., Miller, D. D., Record, K. E., & Griffen, W. O. (1982) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.21.4.575 · Cited by 233
Clinical pharmacology and efficacy of vancomycin in pediatric patients
Lietman, P. S., Schaad, U. B., McCracken, G. H., & Nelson, J. D. (1980) · The Journal of Pediatrics · doi:10.1016/s0022-3476(80)80347-7 · Cited by 219
Vancomycin, a new antibiotic. I. Chemical and biologic properties.
Mh, M., Jm, M., PITTENGER, G. E., Pittenger, R. C., & Wm, S. (1955) · PubMed · Cited by 189

Show all 97 references

Sorted by citations

Items 201–300 of 361

A new and ecological miniaturized method by spectrophotometry for quantification of vancomycin in dosage form
do Nascimento, P. A., Kogawa, A. C., & Salgado, H. R. N. (2021) · Drug Analytical Research · doi:10.22456/2527-2616.112226 · Cited by 12
Statistical analysis of the adverse effects of glycopeptide antibiotics, based on pharmacokinetics and toxicokinetics (PK/TK)
Yoshida, M., Matzno, S., Namba, H., Nishikata, M., & Matsuyama, K. (2006) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-006-0437-z · Cited by 12
In vivo evaluation of temperature‐responsive antimicrobial‐loaded PNIPAAm hydrogels for prevention of surgical site infection
Heffernan, J. M., Overstreet, D. J., Vernon, B. L., McLemore, R. Y., Nagy, T., Moore, R. C., Badha, V. S., Childers, E. P., Nguyen, M. B., Gentry, D. D., et al. (2021) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.34894 · Cited by 12
Pharmacokinetics I: PK-PD Approach, the Case of Antibiotic Drug Development
Sy, S. K. B., & Derendorf, H. (2016) · Springer eBooks · doi:10.1007/978-3-319-27347-1_13 · Cited by 12
Evaluation of Bayesian Predictability of Vancomycin Concentration Using Population Pharmacokinetic Parameters in Pediatric Patients
Ohnishi, A., Yano, Y., Ishibashi, T., Katsube, T., & Oguma, T. (2005) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.20.415 · Cited by 12
Therapeutic Drug Distribution across the Mouse Brain Is Heterogeneous as Revealed by In Vivo, Spatially Resolved Aptamer-Based Sensing
Scida, K., Ornelas‐Gatdula, E., Depasquale, M. J., Carr, G. V., & Arroyo‐Currás, N. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00579 · Cited by 11
Néphrotoxicité de la vancomycine : fréquence et mécanismes
Luque, Y., & Mesnard, L. (2018) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2018.02.009 · Cited by 11
Quantification of Teicoplanin Using the HPLC-UV Method for Clinical Applications in Critically Ill Patients in Korea
Lee, J., Chung, E. K., Kang, S.-W., Lee, H., & Rhie, S. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13040572 · Cited by 11
Clinical applicability of urinary creatinine clearance for determining the initial dose of vancomycin in critically ill patients
Mikami, R., Imai, S., Hayakawa, M., Sugawara, M., & Takekuma, Y. (2021) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.10.008 · Cited by 11
Vancomycin Induced Ferroptosis in Renal Injury Through the Inactivation of Recombinant Glutathione Peroxidase 4 and the Accumulation of Peroxides
Yin, X., Yang, Q., Li, H., Kang, Y., & Li, Z. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s392813 · Cited by 11
Effect of renal clearance on vancomycin area under the concentration–time curve deviations in critically ill patients
Ishigo, T., Ibe, Y., Fujii, S., Kazuma, S., Aigami, T., Kashiwagi, Y., Takada, R., Takahashi, S., Fukudo, M., & Toda, T. (2023) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2023.04.018 · Cited by 11
Effect of various estimates of renal function on prediction of vancomycin concentration by the population mean and Bayesian methods
Tsuji, Y., Hiraki, Y., Mizoguchi, A., Sadoh, S., Sonemoto, E., Kamimura, H., & Karube, Y. (2009) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2008.01015.x · Cited by 11
Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: Intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate
Gatchalian, R. A., Popli, A., Ejaz, A. A., Leehey, D. J., Kjellstrand, C. M., & Ing, T. S. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.19843 · Cited by 11
Treatment of paediatric vancomycin intoxication: a case report and review of the literature
Lemaire, M. J., Connolly, B. L., Harvey, E. A., & Licht, C. P. B. (2010) · Clinical Kidney Journal · doi:10.1093/ndtplus/sfq016 · Cited by 11
Epileptogenic Activity Induced by Teicoplanin and Effects of Some Antiepileptics in Mice
Takechi, K., Ishikawa, T., & Kamei, C. (2008) · Journal of Pharmacological Sciences · doi:10.1254/jphs.08111fp · Cited by 11
Implementation of Vancomycin Therapeutic Monitoring Guidelines: Focus on Bayesian Estimation Tools in Neonatal and Pediatric Patients.
Han, J., Sauberan, J. B., Tran, M. T., Adler‐Shohet, F. C., Michalik, D. E., Tran, T. H., Tran, L., Huy, D., Bradley, J. S., & Lê, J. (2022) · PubMed · doi:10.1097/ftd.0000000000000910 · Cited by 10
Evaluation of the Correspondence between the Concentration of Antimicrobials Entering Sewage Treatment Plant Influent and the Predicted Concentration of Antimicrobials Using Annual Sales, Shipping, and Prescriptions Data
Azuma, T., Nakano, T., Koizumi, R., Matsunaga, N., Ohmagari, N., & Hayashi, T. (2022) · Antibiotics · doi:10.3390/antibiotics11040472 · Cited by 10
Vancomycin population pharmacokinetics and dosing proposal for the initial treatment in obese adult patients
Polášková, L., Murínová, I., Gregorová, J., Slanař, O., & Šíma, M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1364681 · Cited by 10
Pharmacokinetics of ceftriaxone, gentamicin, meropenem and vancomycin in liver cirrhosis: a systematic review
Comce, M. H., Weersink, R. A., Beuers, U. H., van Hest, R. M., & Lantinga, M. A. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae310 · Cited by 10
Evaluation of a vancomycin dosing nomogram in obese patients weighing at least 100 kilograms
Bowers, R. D., Cooper, A. A., Wente, C. L., Wilson, D. T., Johnson, S. W., & Drew, R. H. (2018) · Pharmacy Practice · doi:10.18549/pharmpract.2018.03.1204 · Cited by 10
The “Culture” of Pain Control: A Review of Opioid-Induced Dysbiosis (OID) in Antinociceptive Tolerance
Mischel, R. A., Muchhala, K. H., Dewey, W. L., & Akbarali, H. I. (2019) · Journal of Pain · doi:10.1016/j.jpain.2019.11.015 · Cited by 11
Evaluation of Bayesian Predictability of Vancomycin Concentration in Patients with Various Degrees of Renal Function.
Ohnishi, A., Yano, Y., SHIMAMURA, K., & Oguma, T. (2001) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.24.1446 · Cited by 10
Pharmacokinetics of antimicrobial therapy
Stevens, R. C., & Rodman, J. H. (1998) · Seminars in Pediatric Infectious Diseases · doi:10.1016/s1045-1870(98)80016-2 · Cited by 10
Initial dosing of intermittent vancomycin in adults: estimation of dosing interval in relation to dose and renal function
Šíma, M., Hartinger, J. M., Grus, T., & Slanař, O. (2019) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2019-002013 · Cited by 10
How vancomycin is used in Australasia – A survey
Duffull, S. B., Chambers, S. T., & Begg, E. J. (1993) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.1993.tb04723.x · Cited by 10
Toxicologic and pharmacokinetic evaluation of a case of vancomycin intoxication during continuous ambulatory peritoneal dialysis
Hekster, Y. A., Vree, T. B., Weemaes, C. M. R., & Rotteveel, J. J. (1986) · Pharmacy World & Science · doi:10.1007/bf02280053 · Cited by 10
A Meta-Analysis on the Performance of Cystatin C- versus Creatinine-based eGFR Equations in Predicting Vancomycin Clearance
Tahir, N. A. M., Saffian, S. M., Islahudin, F. H., Gafor, A. H. A., & Makmor‐Bakry, M. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e306 · Cited by 9
Prospective, double-blind, randomized trial of teicoplanin versus vancomycin for the therapy of vascular access-associated bacteremia caused by gram-positive pathogens
Rolston, K. V., Bodey, G. P., & Chow, A. W. (1999) · Journal of Infection and Chemotherapy · doi:10.1007/s101560050037 · Cited by 9
Recovery rates of combination antibiotic therapy using in vitro microdialysis simulating in vivo conditions
Dhanani, J., Parker, S. L., Lipman, J., Wallis, S. C., Cohen, J., Fraser, J. F., Barnett, A. G., Chew, M. S., & Roberts, J. A. (2018) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2018.07.003 · Cited by 9
Optimisation de la prescription de la vancomycine : étude prospective observationnelle dans un centre hospitalo-universitaire parisien
Taieb, F., Monnier, A. L., Bille, E., Lanternier, F., Mechai, F., Ribadeau-Dumas, F., Maenulein, E., Forge, C., Corriol, O., Nassif, X., et al. (2009) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2009.10.004 · Cited by 9
Microbiome-derived bacterial lipids regulate gene expression of proinflammatory pathway inhibitors in systemic monocytes
Mihori, S., Nichols, F. C., Provatas, A. A., Matz, A., Zhou, B., Blesso, C. N., Panier, H. A., Daddi, L., Zhou, Y., & Clark, R. B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1415565 · Cited by 8
Resilient nanostructured bioanalytic microneedle longitudinally monitors preclinical renal and hepatic drug clearance and dysfunction
Zhu, J., Cheng, X., Bahramian, M. B., Yao, K., Li, Z., Hu, B., Wu, T., Sabet, K. A., Cui, J., Tan, J., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adr5493 · Cited by 8
Population pharmacokinetics and target attainment analysis of vancomycin after intermittent dosing in adults with cystic fibrosis
Yellepeddi, V., Lindley, B., Radetich, E., Kumar, S. S., Bhakta, Z. N., Leclair, L., Parrot, M., & Young, D. C. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00992-23 · Cited by 8
Comparison of Vancomycin Clearance Between Augmented Renal Clearance and Normal Renal Function in Critically Ill Infants: A Population Pharmacokinetics Study
Guang-ming, H., Qiu, Y., Liu, T., & Lu, J. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2029 · Cited by 8
Drug points: Systemic response to intralesional steroid therapy
Dziewulski, P. G., Gault, D. T., & Davis, P. K. B. (1988) · BMJ · doi:10.1136/bmj.296.6615.137-b · Cited by 8
Increased vancomycin dosing requirements in sickle cell disease due to hyperfiltration-dependent and independent pathways
Han, J., Zhang, X., Oderinde, J., Saraf, S. L., Gowhari, M., Hassan, J., Jain, S., Gordeuk, V. R., & Molokie, R. E. (2017) · Haematologica · doi:10.3324/haematol.2017.169128 · Cited by 7
Influences of Everninomicin, Vancomycin and Teicoplanin on Chemical Mediator Release From Rat Peritoneal Mast Cells
Sugimoto, Y., Iba, Y., Utsugi, K., & Kamei, C. (2000) · The Japanese Journal of Pharmacology · doi:10.1016/s0021-5198(19)30564-5 · Cited by 7
Initial dosing regimen of vancomycin to achieve early therapeutic plasma concentration in critically ill patients with MRSA infection based on APACHE II score
Imaura, M., Yokoyama, H., Kohata, Y., Kanai, R., Kohyama, T., Idemitsu, W., Maki, Y., Igarashi, T., Takahashi, H., Kanno, H., et al. (2014) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-014-0246-1 · Cited by 7
Drug points: Delirium in a patient treated with mainserin
Fisch, R. Z., & Alexandrowitz, A. (1988) · BMJ · doi:10.1136/bmj.296.6615.137-c · Cited by 7
Drug points: Penile erection due to nifedipine
Rayner, H. C., May, S., & Walls, J. (1988) · BMJ · doi:10.1136/bmj.296.6615.137 · Cited by 7
Population Pharmacokinetics and Dosage Optimization of Vancomycin in Pediatric Patients with Skin and Soft Tissue Infections, Bone, and Joint Infections
Lv, M., Yang, P., Zhang, S., Wang, L., Sun, K., & Zhao, L. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01624-22 · Cited by 6
Managing the clinical effects of drug-induced intestinal dysbiosis with a focus to antibiotics: Challenges and opportunities
Gnatzy, L., Ismailos, G., Vertzoni, M., & Reppas, C. I. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106510 · Cited by 6
Oral vancomycin use and incidence of vancomycin-resistant enterococci: time-series analysis
Bae, S., Cho, K., Park, I., Kim, J., Han, H., Jung, J., Kim, H. B., & Lee, S. (2024) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-024-01498-y · Cited by 6
Two Innovative Approaches to Optimize Vancomycin Dosing Using Estimated AUC after First Dose: Validation Using Data Generated from Population PK Model Coupled with Monte-Carlo Simulation and Comparison with the First-Order PK Equation Approach
Liu, Q., Huang, H., Xu, B., Li, D., Liu, M., Shaik, I. H., & Wu, X. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051004 · Cited by 6
Participation of GABA-ergic system in epileptogenic activity induced by teicoplanin in mice
Takechi, K., Fujiwara, A., Watanabe, Y., & Kamei, C. (2009) · Epilepsy Research · doi:10.1016/j.eplepsyres.2009.01.006 · Cited by 6
Role of glycopeptide antibiotics in the treatment of febrile neutropenic patients
SMITH, S. R., Cheesbrough, J., Harding, I., & Davies, J. M. (1990) · British Journal of Haematology · doi:10.1111/j.1365-2141.1990.tb07938.x · Cited by 6
Dosificación de antibióticos en el tratamiento de las infecciones por SARM en pacientes con insuficiencia renal aguda sometidos a técnicas continuas de depuración extrarrenal
Carcelero, E., & Soy, D. (2011) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2011.09.013 · Cited by 5
Influence of cerebrospinal fluid drainage and other variables on the plasma vancomycin trough levels in postoperative neurosurgical patients
Chen, C., Xu, P., Xu, T., Zhou, K., & Zhu, S. (2020) · British Journal of Neurosurgery · doi:10.1080/02688697.2020.1769023 · Cited by 5
Methods of Therapeutic Drug Monitoring to Guide Vancomycin Dosing Regimens: Trough Concentration versus Ratio of Area Under the Curve to Minimum Inhibitory Concentration
Sault, A. D., Parent, M., & Simard, C. (2022) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.v75i2.3114 · Cited by 5
Examination of Factors Affecting Efficacy and Adverse Effect, for the Retrospective Study of Vancomycin Hydrochloride (VCM)
Tanaka, M., Orii, T., Kobayashi, H., & Hirono, S. (2001) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.121.621 · Cited by 5
Glycopeptides and Lipoglycopeptides
Bryskier, A., & Veyssier, P. (2014) · ASM Press eBooks · doi:10.1128/9781555815929.ch31 · Cited by 5
Drug points: Exfoliative reaction to vancomycin
Neal, D., Morton, R., Bailie, G. R., & Waldek, S. (1988) · BMJ · doi:10.1136/bmj.296.6615.137-a · Cited by 5
Involvement of TLR4 in Acute Hepatitis Associated with Airway Infection of Murine γ-Herpesvirus 68
Kanai, K., Kageyama, S., & Yoshie, O. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200653 · Cited by 4
Physiologically Based Pharmacokinetic Modeling of Vancomycin and its Comparison with Population Pharmacokinetic Model in Neonates
Cao, A., Li, Q., Han, M., Liu, Q., Liang, H., Tan, L., & Guan, Y. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.6126 · Cited by 4
Multicompartment Drug Monitoring Reveals Paired Brain−Liver Kinetics and Selective Central Nervous System Barrier Permeability in Rats
Yuan, Y., Scida, K., Carr, G. V., Grohn, K., & Arroyo‐Currás, N. (2026) · ACS Sensors · doi:10.1021/acssensors.5c04463 · Cited by 4
Multidrug-Resistant Gram-Positive Bacterial Infections
Jung, Y., & Kim, H. B. (2015) · Korean Journal of Medicine · doi:10.3904/kjm.2015.88.5.487 · Cited by 4
Nephrotoxicity Reduction by Ceftriaxone plus Vancomycin (Vancoplus) Reconstituted with VRP 1020 in Blood of Mus musculus Mice
Soni, A., Chaudhary, M., & Dwivedi, V. K. (2009) · Journal of Pharmacology and Toxicology · doi:10.3923/jpt.2009.107.116 · Cited by 4
Correlation between vancomycin clearance and cystatin C‐based glomerular filtration rate in paediatric patients
Oh, Y., Park, S., Park, E., Lee, J.-H., Lee, H., Kim, J., & Cho, J. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14733 · Cited by 4
Evaluation of the Association between Trough and Area Under the Curve to Minimum Inhibitory Concentration Ratio (AUC24/MIC) of Vancomycin in Infected Patients with Methicillin Resistant Staphylococcus aureus (MRSA)
Esmaeili, A., Salehi, M., Makhdoomi, N., Ardakani, Y. H., Rajabi, M., & Namazi, S. (2020) · Pharmaceutical Sciences · doi:10.34172/ps.2020.70 · Cited by 4
Development of a decision flowchart to identify the patients need high-dose vancomycin in early phase of treatment
Yamaguchi, R., Kani, H., Yamamoto, T., Tanaka, T., & Suzuki, H. (2022) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-021-00231-w · Cited by 4
Does calculation method matter for targeting vancomycin area under the curve?
Chang, J. H. T., Patel, D., Vega, A. D., Claeys, K. C., Heil, E. L., & Scheetz, M. H. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac151 · Cited by 4
Nephrotoxicity of teicoplanin in rats.
Yoshiyama, Y., Yazaki, T., Kanke, M., & Beauchamp, D. (2000) · PubMed · Cited by 4
Les volumes apparents de distribution des antibiotiques: évaluation, intérêt et limites
Bronner, S., Levêque, D., & Jehl, F. (2006) · Antibiotiques · doi:10.1016/s1294-5501(06)70794-4 · Cited by 4
Immunological response to Cryptosporidium species.
Heyworth, M. F. (1990) · Gut · doi:10.1136/gut.31.12.1423-a · Cited by 4
Use of elemental diets in the treatment of Crohn's disease by gastroenterologists.
Payne-James, J. J., & Silk, D. B. A. (1990) · Gut · doi:10.1136/gut.31.12.1424-a · Cited by 4
Vancomycin in resistant hepatic encephalopathy.
Forbes, A., & Murray‐Lyon, I. M. (1990) · Gut · doi:10.1136/gut.31.12.1424-b · Cited by 4
Clinical Pharmacokinetics of Anti-Infectives
Matzke, G. R., & Kovarik, J. M. (1992) · Palgrave Macmillan UK eBooks · doi:10.1007/978-1-349-13175-4_34 · Cited by 4
Self-citation
The Effects of the Early and Late Phases of Septic Shock on the Population Pharmacokinetics of Vancomycin
Lexnoi, T., Boonpeng, A., Santimaleeworagun, W., Chaisiri, K., Dechsanga, J., Vattanavanit, V., Ungthammakhun, C., & Sitaruno, S. (2025) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70009 · Cited by 3
Development of Novel Dosing Strategy According to the Area under the Concentration-Time Curve for Vancomycin
Oda, K. (2022) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.22-00131 · Cited by 3
Comparative In Vitro Activity of New Lipoglycopeptides and Vancomycin Against Ocular Staphylococci and Their Toxicity on the Human Corneal Epithelium
André, C., Islam, M. M., Paschalis, E. I., & Bispo, P. J. M. (2022) · Cornea · doi:10.1097/ico.0000000000003197 · Cited by 3
Prediction of Area Under the Curve from Urinary Vancomycin Concentrations Measured Using a Simple Method
Oshima, Y., Matsumoto, M., Munakata, S., Tokimatsu, I., Hattori, N., Kotani, T., Kusumoto, S., Sagara, H., & Kato, M. (2025) · The AAPS Journal · doi:10.1208/s12248-025-01021-0 · Cited by 3
Contribution of Non-renal Clearance to the Elimination of Vancomycin during Repeated Intravenous Administration in Elderly Patients.
Cho, T., Uchida, E., Oguma, T., Uchida, N., YASUDA, K., Shimada, K., Kobayashi, S., & Yasuhara, H. (1995) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.26.743 · Cited by 3
Vancomycin
Smith, R. G. (2004) · Journal of the American Podiatric Medical Association · doi:10.7547/0940389 · Cited by 3
In vitro and in vivo local tolerability of a synergistic anti‐tuberculosis drug combination intended for pulmonary delivery
Ravon, F., Menchi, E., Lambot, C., Kattar, S. A., Chraibi, S., Remmelink, M., Fontaine, V., & Wauthoz, N. (2022) · Journal of Applied Toxicology · doi:10.1002/jat.4381 · Cited by 3
Intrawound Vancomycin Powder in Primary Total Hip Arthroplasty: A Prospective Quality Control Study
Doxey, S. A., Urdahl, T. H., Solaiman, R. H., Wegner, M. N., Cunningham, B. P., & Horst, P. K. (2024) · The Journal of Arthroplasty · doi:10.1016/j.arth.2024.03.063 · Cited by 3
Subgroup-based model selection to improve the prediction of vancomycin concentrations
Laas, H. K., Metsvaht, T., Tamme, K., Karjagin, J., Naber, K., Afanasjev, A., Tiivel, C., Lutsar, I., & Soeorg, H. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00174-25 · Cited by 3
Adverse effects of vancomycin in children: a review of 22 cases
Reis, A. G., & Grisi, S. J. F. E. (1997) · Sao Paulo Medical Journal · doi:10.1590/s1516-31801997000300010 · Cited by 3
Performance of Methods to Assess Kidney Function in a Predominantly Overweight Sample of Patients with Liver Disease
Hudson, J. Q., Owens, H., Fleckenstein, J. F., LOVELESS, V. S., Krauss, A. G., & Hak, L. J. (2012) · Renal Failure · doi:10.3109/0886022x.2012.745786 · Cited by 3
Quality Comparison of Different Vancomycin Hydrochloride Preparations for Injection
Yamasaki, H., Miyano, N., Oie, S., & Kamiya, A. (2008) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.34.860 · Cited by 3
New recommendations for vancomycin dosage for patients with MRSA pneumonia with various degrees of renal function impairment
Yoshida, M., Yasuda, N., Nishikata, M., Okamoto, K., Uchida, T., & Matsuyama, K. (2005) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-005-0394-y · Cited by 3
Evaluation of Concentration Errors and Inappropriate Dose Tailoring of Tacrolimus Caused by Sampling-Time Deviations in Pediatric Patients With Primary Nephrotic Syndrome
Wang, J., Gao, P., Zhang, H., Hu, Y. W., Ni, Y., Zhu, Z., Zhang, L., Wang, H., Yang, J., Ji, C., et al. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000717 · Cited by 3
Appropriate Use of the Anti-Methicillin-Resistant Staphylococcus aureus Agents in Retrospective Study
Nakamura, Y., Yokoyama, I., HASHIMOTO, N., Hasegawa, A., Nakasa, H., Nakamura, H., Watanabe, M., Nomura, F., Watanabe, A., Igari, H., et al. (2008) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.128.1073 · Cited by 3
Pharmacokinetics and Pharmacodynamics of Antistaphylococcal Antibiotics in Continuous Ambulatory Peritoneal Dialysis Patients
Keller, E. (1993) · Peritoneal Dialysis International · doi:10.1177/089686089301302s92 · Cited by 3
Three methods to optimise polymyxin B dosing using estimated AUC after first dose: validation with the data generated by Monte Carlo simulation
Liu, Q., Zhou, J., Zheng, Y., Xu, B., Li, D., Liu, M., Zhang, X., & Wu, X. (2024) · Xenobiotica · doi:10.1080/00498254.2024.2370051 · Cited by 2
Therapeutic drug monitoring of vancomycin in a patient with Duchenne muscular dystrophy (DMD): A case report
Lee, S. W., Yoon, S., Yu, K., & Lee, S. (2016) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2016.24.3.124 · Cited by 2
Vancomycin Flushing Syndrome Due to Oral Vancomycin in Chronic Kidney Disease Patients: A Case Report
Yadav, S., Hashmi, M. U., Shah, S., Sarwar, A., & Ibrahim, R. (2022) · Cureus · doi:10.7759/cureus.28024 · Cited by 2
Vancomycin loading dose individualization in a population of obese patients undergoing haemodialysis based on population pharmacokinetic model
Polášková, L., Hartinger, J. M., Murínová, I., Michálek, P., Slanař, O., & Šíma, M. (2024) · Journal of Chemotherapy · doi:10.1080/1120009x.2024.2367937 · Cited by 2
Mathematical modeling of vancomycin release from Poly-L-Lactic Acid-Coated implants
Thamvasupong, P., & Viravaidya‐Pasuwat, K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0311521 · Cited by 2
Pediatric Primary Sclerosing Cholangitis
Hosseini, D. M., & Mack, C. L. (2016) · Springer eBooks · doi:10.1007/978-3-319-40908-5_6 · Cited by 2
Evaluation of Japanese GFR Estimation Equation for Setting Initial Dose of Vancomycin-Comparison with Cockcroft & Gault equation-
Takagi, A., Nagata, M., Iwakiri, T., Okumura, M., & 有森, 和. (2010) · Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) · doi:10.5649/jjphcs.36.587 · Cited by 2
Pharmacokinetic-Pharmacodynamic and Clinical Considerations for Extended- and Continuous-Infusion Antibiotics
Masich, A. M., Omecene, N. E., Lai, J., Ong, R., Gravatt, L. A. H., & Khan, R. W. (2023) · Clinical Microbiology Newsletter · doi:10.1016/j.clinmicnews.2023.07.003 · Cited by 2
Flowchart for predicting achieving the target area under the concentration-time curve of vancomycin in critically ill Japanese patients: A multicenter retrospective study
Ishigo, T., Fujii, S., Ibe, Y., Aigami, T., Nakano, K., Fukudo, M., Yoshida, H., Tanaka, H., Ebihara, F., Maruyama, T., et al. (2023) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2023.11.001 · Cited by 2
Frequency of Decreased Renal Function between Patients Treated with Brand and Generic Products of Vancomycin Hydrochloride Injection
Izuwa, Y., Ueshima, S., Sato, T., OKAZAKI, M., Aiba, T., Kawasaki, H., Kurosaki, Y., & Sendo, T. (2008) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.128.1493 · Cited by 2
Vancomycin lung concentration in acute and hyperacute rejection models of lung transplantation in rats☆☆☆
Pieróg, J., Kubisa, B., Droździk, M., Wójcik, J., Bielewicz, M., Pankowski, J., Safranow, K., & Grodzki, T. (2010) · European Journal of Cardio-Thoracic Surgery · doi:10.1016/j.ejcts.2010.02.002 · Cited by 2
Les glycopeptides restent-ils le traitement de référence des infections nosocomiales à SARM ?
Brun‐Buisson, C. (2004) · Médecine et Maladies Infectieuses · doi:10.1016/s0399-077x(04)80002-7 · Cited by 2
In vivo tolerability of topical telavancin versus vancomycin in a murine ocular model
Fenniri, I., Bispo, P. J. M., & André, C. (2026) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkag250 · Cited by 1
Appropriate Use of Glycopeptide Antibiotics and Therapeutic Drug Monitoring for Invasive Infections
Kim, S., Lee, S.-Y., & Kang, C.-I. (2021) · Korean Journal of Medicine · doi:10.3904/kjm.2021.96.6.463 · Cited by 1
Intrawound vancomycin powder in primary total knee arthroplasty: Does it reduce early postoperative infection?
Doxey, S. A., Urdahl, T. H., Solaiman, R. H., Wegner, M. N., Parikh, H. R., Cunningham, B. P., & Horst, P. K. (2024) · The Knee · doi:10.1016/j.knee.2024.10.008 · Cited by 1
Population Pharmacokinetics and AUC‐Based Dose Optimization of Vancomycin in Chinese Neonates
Yang, C., Wei, S., Wang, B., Yang, J., Zhao, Z., Xu, D., & Mei, S. (2025) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1155/jcpt/6935260 · Cited by 1
A Novel Human Stem Cell Culture Model for Severe Traumatic Brain Injury Reflecting Sexual Dimorphism in Heterotopic Ossification
Joneleit, J., Leimkühler, P., Niemann, T., Ruwe, M., Jantos, C. A., Wähnert, D., Kaltschmidt, C., Vordemvenne, T., & Kaltschmidt, B. (2025) · Cells · doi:10.3390/cells14191491 · Cited by 1

Authors: Matzke, G. R., Zhanel, G. G., & Guay, D. R. P.
Affiliations: University of Minnesota (US)
ORCID: Zhanel, G.G.
Guay, D.R.P.
Venue: Clinical Pharmacokinetics
Publisher: Springer Science and Business Media LLC
Published: 1986
Volume: 11
Issue: 4
Pages: 257-282
ISSN: 0312-5963 (ISSN-L)
DOI: 10.2165/00003088-198611040-00001
OpenAlex: W1992743376
Cited by: 360
References: 97
Citations by year: 2026: 6 · 2025: 12 · 2024: 17 · 2023: 12 · 2022: 19 · 2021: 15 · 2020: 23 · 2019: 16 · 2018: 11 · 2017: 10 · 2016: 12 · 2015: 11 · 2014: 11 · 2013: 4 · 2012: 13
FWCI: 5.65
Type: journal article
Language: en
Open access: closed
Locations: Clinical Pharmacokinetics (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
Keywords: vancomycin, pharmacokinetics, oral vancomycin, pseudomembranous colitis, renal excretion, glomerular filtration, hepatic conjugation, end-stage renal disease, tissue distribution, cerebrospinal fluid penetration, meningeal infection, drug toxicity, methicillin-resistant staphylococci, therapeutic drug monitoring
MeSH terms: Adult, Aged, Child, Child, Preschool, Humans, Infant, Infant, Newborn, Kinetics, Middle Aged, Vancomycin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Clinical Pharmacokinetics of Vancomycin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks